The Delaware Court of Chancery has denied a motion by shareholders of BioClinica Inc. to expedite their lawsuit against the company, holding that the company did not adopt preclusive deal protection measures when it agreed to a $123 million buyout from JLL Partners Inc. The court's decision means that any trial will not likely start until after the merger's expected completion date of March 11.
Font Size: 
Poison Pill Not Preclusive in $123 Mil. BioClinica Merger, Chancery Court Rules
Delaware Business Court Insider
March 6, 2013
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.
